AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CalciMedica's CM5480 shows promise in PAH treatment, cardiac benefits support AKI therapy.
ByAinvest
Wednesday, Nov 12, 2025 7:03 am ET1min read
• CalciMedica's CM5480 shows potential as PAH therapy, both as monotherapy and in combination with existing treatments. • CM5480 acts by selectively and potently inhibiting CRAC channels. • Preclinical data supports cardiac benefit for CRAC channel inhibition in acute kidney injury (AKI). • Phase 2 KOURAGE trial for AKI is underway with data expected in 1H 2026. • CM5480 is a potential first-in-class, differentiated therapy for PAH.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet